Rasgon B M
Department of Head and Neck Surgery, Kaiser Permanente Medical Center, 280 West MacArthur Boulevard, Oakland, CA 94611-5693, U.S.A.
Laryngoscope. 2001 Aug;111(8):1366-72. doi: 10.1097/00005537-200108000-00010.
OBJECTIVES/HYPOTHESIS: Because sentinel lymph nodes are the first lymph nodes that drain a primary cancer site, results of sentinel lymph node (SLN) biopsy indicate status of the regional lymph nodes. Preoperative lymphoscintigraphy and intraoperative combined application of the handheld gamma probe and blue-dye technique (i.e., the "combined technique") was used previously to accurately identify the SLN, mostly in melanoma of the extremities and trunk and, sometimes, in melanoma of the head or neck, which is anatomically complex. Because of this complexity, melanoma in the head or neck is inherently problematic to treat: Localization of the SLN can be difficult or impossible because the primary cancer site can be near or overlapping the nodal basin. The objective of the present study was to determine the technical modifications and other considerations that can make SLN localization feasible in cases of melanoma occurring near or overlapping the nodal basin in the head or neck.
STUDY DESIGN/METHODS: In a retrospective study of clinical records containing our database of melanoma diagnoses made between January 1996 and December 1999, we identified 27 patients diagnosed with stage I or II primary melanoma of the head or neck with clinically negative neck nodes who also had had preoperative lymphoscintigraphy. Of the 27 patients (17 male and 10 female patients; mean age, 54 y), 24 had SLN biopsy by intraoperative localization using both the handheld gamma probe and the blue-dye technique.
Among the 27 patients who had SLN mapping, a median Breslow thickness of 1.8 mm was noted. Sentinel lymph node was noted at preoperative lymphoscintigraphy in 26 (96%) of the 27 patients. Activity of technetium Tc 99m (Tc-99m) sulfur colloid injected ranged from 10 to 1000 microCi (0.37 to 37 megabecquerel [MBq]). Intraoperative use of the combined technique for sentinel lymphadenectomy was successful in 92% of patients. Sentinel lymph nodes were identified in all 14 patients who received Tc-99m sulfur colloid at an activity level less than 60 microCi (2.2 MBq); mean activity level of injected TC-99m sulfur colloid was 28 microCi (1.04 MBq). Sentinel lymph nodes were identified in 8 (80%) of 10 patients who received Tc-99m sulfur colloid at an activity level greater than 100 microCi (3.7 MBq); mean activity of injected Tc-99m sulfur colloid in these patients was 482 microCi (17.8 MBq). A mean number of 1.4 sentinel lymph nodes per patient was identified at preoperative lymphoscintigraphy, and a mean number of 3 sentinel lymph nodes per patient was identified intraoperatively using the combined technique. Tumor recurrence was seen in 2 (10%) of the 19 patients who had cancer-free SLN at mean follow-up of 18 months (range, 1 to 47 mo). Sentinel lymphadenectomy of the parotid region did not injure the facial nerve in any patients.
For patients with primary melanoma that is near or overlaps the nodal basin in the head or neck, SLN biopsy can be accurately performed using Tc-99m sulfur colloid at low activity levels (10 microCi to 60 microCi [0.37 to 2.2 MBq]. However, background radiation from the primary injection site can incorporate the SLN, making localization at preoperative lymphoscintigraphy difficult if not impossible; therefore, the high doses commonly used for melanoma of the extremities and trunk (500 to 2000 microCi [18.5 to 74 MBq]) should not be used for melanoma of the head or neck if the primary site is near or overlaps the nodal basin. In addition, absorption of Tc-99m sulfur colloid by salivary glands increases background radiation in the nodal basin; therefore, use of the handheld gamma probe for intraoperative localization of SLN can be problematic in regions where lymph nodes are adjacent to or within the substance of the salivary gland (i.e., the submandibular and parotid glands).
目的/假设:由于前哨淋巴结是引流原发癌部位的第一组淋巴结,前哨淋巴结(SLN)活检结果可表明区域淋巴结的状态。此前,术前淋巴闪烁显像以及术中手持γ探测仪与蓝色染料技术联合应用(即“联合技术”)被用于准确识别SLN,主要用于四肢和躯干黑色素瘤,有时也用于解剖结构复杂的头颈部黑色素瘤。由于这种复杂性,头颈部黑色素瘤的治疗存在固有问题:由于原发癌部位可能靠近或重叠淋巴结区域,SLN的定位可能困难甚至无法实现。本研究的目的是确定能够使头颈部靠近或重叠淋巴结区域的黑色素瘤病例中SLN定位可行的技术改进及其他注意事项。
研究设计/方法:在一项对1996年1月至1999年12月间黑色素瘤诊断数据库临床记录的回顾性研究中,我们确定了27例诊断为头颈部I期或II期原发性黑色素瘤且颈部淋巴结临床阴性的患者,这些患者均接受了术前淋巴闪烁显像。27例患者(17例男性和10例女性患者;平均年龄54岁)中,24例通过术中使用手持γ探测仪和蓝色染料技术进行定位接受了SLN活检。
在27例行SLN定位的患者中,Breslow厚度中位数为1.8 mm。27例患者中有26例(96%)在术前淋巴闪烁显像时发现前哨淋巴结。注射的锝Tc 99m(Tc-99m)硫胶体活性范围为10至1000微居里(0.37至37兆贝克勒尔[MBq])。术中联合技术用于前哨淋巴结切除在92%的患者中成功。在所有14例接受活性水平低于60微居里(2.2 MBq)的Tc-99m硫胶体的患者中均识别出前哨淋巴结;注射的Tc-99m硫胶体平均活性水平为28微居里(1.04 MBq)。在10例接受活性水平高于100微居里(3.7 MBq)的Tc-99m硫胶体的患者中有8例(80%)识别出前哨淋巴结;这些患者中注射的Tc-99m硫胶体平均活性为482微居里(17.8 MBq)。术前淋巴闪烁显像时每位患者平均识别出1.4个前哨淋巴结,术中使用联合技术每位患者平均识别出3个前哨淋巴结。在平均随访18个月(范围1至47个月)的19例SLN无癌的患者中有2例(10%)出现肿瘤复发。腮腺区域的前哨淋巴结切除在所有患者中均未损伤面神经。
对于头颈部靠近或重叠淋巴结区域的原发性黑色素瘤患者,使用低活性水平(10微居里至60微居里[0.37至2.2 MBq])的Tc-99m硫胶体可准确进行SLN活检。然而,来自初次注射部位的本底辐射可能包含前哨淋巴结,这使得术前淋巴闪烁显像时定位即便不是不可能也会很困难;因此,如果原发部位靠近或重叠淋巴结区域,用于四肢和躯干黑色素瘤的常用高剂量(500至2000微居里[18.5至74 MBq])不应应用于头颈部黑色素瘤。此外,唾液腺对Tc-99m硫胶体的摄取会增加淋巴结区域的本底辐射;因此,在淋巴结与唾液腺实质相邻或位于其中的区域(即下颌下腺和腮腺),使用手持γ探测仪进行术中SLN定位可能存在问题。